CDK6, a new target in MLL-driven leukemia.

Abstract

In this issue of Blood, Placke et al identify the cell-cycle regulator CDK6 as a promising new target in mixed lineage leukemia (MLL)-rearranged acute myeloid leukemia (AML) and show that its downregulation or pharmacological inhibition leads to growth inhibition and differentiation of MLL-driven leukemic cells. 
DOI: 10.1182/blood-2014-05-572917

Topics

  • Presentations referencing similar topics